CNS Pharmaceuticals Q2 net loss widens, cash rises after financing - CNSP News | RalliesCNS Pharmaceuticals Q2 net loss widens, cash rises after financing
C
CNSP• Outlook
- Company expects to in-license or acquire one or more assets by year end 2026
- Company says existing cash resources are sufficient to fund operations beyond the next twelve months
- Future R&D expenses will depend on timing and nature of any assets acquired or licensed
Overview
- Biotechnology company's Q2 net loss widened to $2.6 mln, loss per share was $0.37
- Company ended Q2 with $20 mln in cash after $22.5 mln private placement
- CNS advancing strategy to diversify pipeline, expects to acquire new assets by year end
Result Drivers
- Capital infusion - Q2 results driven by $22.5 mln private placement, boosting cash position and extending operating runway
- Strategic pivot - Co focused on diversifying pipeline beyond glioblastoma, actively evaluating business development opportunities
- Legacy programs winding down - Completion of Berubicin clinical trial and out-licensing discussions for legacy assets impacted R&D expenses
•
